Home
overview
A unique opportunity to learn from leading industry experts including:
Dr Gunnar Kjellin, Director, Research & Development, Portfolio Management, AstraZeneca
Dr Roy Bullingham, Vice President, Clinical Pharmacology, Pharmacia
Alexander Johns, Chairman, bioStrategies Group
Nigel Illingworth, Managing Consultant, IBM Business Consulting Services
Dr Mark Seidler, Senior Engagement Manager, Life Sciences Practice, Strategic Decisions Group (SDG)
Michael Menard, President, North America, The GenSight Group

Benefits of attending:

  • Learn from leading experts in the field
  • Understand the opportunities and advantages in portfolio planning
  • Identify the key issues surrounding portfolio management
  • Find out about successful portfolio strategies
  • Take advantage of the networking opportunities
  • Meet the key decision makers

    “This conference provides much needed insight for R & D decision making – the most crucial everyday challenge in the pharmaceutical business today.”
    Michael Menard, President, North America, GenSight

  • Conference programme

    8:30 Registration and Coffee

    9:00 Chairman's Opening Remarks

    Michael Menard

    Michael Menard, President, North America, The GenSight Group

    9:10 KEYNOTE

    Dr Gunnar Kjellin

    Dr Gunnar Kjellin, Director, Research & Development, Portfolio Management, AstraZeneca

  • The company’s role in portfolio management
  • Why is portfolio management important?
  • The marketing/scientific relationship
  • The complexity of a pharmaceutical product portfolio
  • Objectives of portfolio management
  • Challenges in portfolio management
  • 9:40 ACHIEVING DECISION EXCELLENCE IN R & D PORTFOLIO MANAGEMENT

    Michael Menard

    Michael Menard, President, North America, The GenSight Group

  • Reduce the ‘Perceptual Bias’ that often leads to poor decision making
  • Bring clarity to large amounts of relevant information
  • Focus thought through data visualisation: “Clear and precise seeing leads to clear and precise thinking”
  • Gain clear and compelling insights into the total portfolio
  • Utilise genetic-algorithm search and optimisation techniques to select the ideal portfolio to maximise the return from constrained resources
  • 10:20 TWENTY YEARS SINCE THE FIRST BIOTECHNOLOGY DRUG WAS APPROVED BY FDA

    Carole Jones

    Carole Jones, Consultant, IMS Global Consulting

  • Comparing the uptake of biotechnology products in Europe and the U.S.
  • Identifying which therapeutic areas are proving the most fertile for biotechs in each market
  • Growth drivers in Japan – how different is this market turning out to be?
  • 11:00 Morning Coffee

    11:20 PORTFOLIO MANAGEMENT IN THE SMALL CAP ENVIRONMENT

    Dr Chris Wood

    Dr Chris Wood, Chief Executive Officer, Bioenvision

  • A small cap perspective of portfolio management
  • Indicators for new products
  • Budget control and supervision
  • Timing and choice of development partners
  • Off-label development
  • Sites for portfolio development
  • 12:00 REAL OPTIONS

    Gary Johnson

    Gary Johnson, Managing Director, Inpharmation
    View Bio

  • What are real options and why are they so popular/interesting?
  • Has options valuation been validated (in their original setting – financial derivatives – and for real options)?
  • When does a real options approach make a significant difference to your valuations?
  • Mistakes you can make using an options approach
  • Can the insights from real options be used simply without getting lost in arcane mathematics?
  • 12:40 Networking Lunch

    14:00 STRATEGIES FOR OPTIMISING PORTFOLIO DECISIONS

    Dr David Webster

    Dr David Webster, President, The Webster Consulting Group

  • Diagnosis of portfolio decision-making distortions
  • Why existing approaches have failed to eliminate distortions
  • Portfolio decision optimisation – strategies and case study
  • 14:40 ORGANISING FOR STRATEGIC & VALUE-BASED PORTFOLIO MANAGEMENT

    John Rountree

    John Rountree, Director, Integral

  • Aligning strategic and quantitative measures
  • Ensuring transparency and credibility in data
  • Engaging the strategic debate
  • Bringing flexibility to portfolio decision making
  • 15:20 Afternoon Tea

    15:40 NEW IDEAS IN RISK MANAGEMENT

  • Different risks – same challenges
  • The oil & gas revolution – integrated uncertainty
  • Demands of the global client on the insurance industry
  • Ideas for the pharmaceutical industry
  • System dynamics – a process for integration
  • Adam Mitchell

    Adam Mitchell, Consultant, Paras Consulting

    Adam Mitchell

    Adam Mitchell, Consultant, Paras Consulting

    16:20 PANEL DISCUSSION

    Chaired by: Dr Stephen Black

    Chaired by: Dr Stephen Black, Principal Consultant, PA Consulting

    17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Re-registration & Coffee

    9:00 Chairman's Opening Remarks

    Dr Mark Seidler

    Dr Mark Seidler, Senior Engagement Manager, Life Sciences Practice, Strategic Decisions Group (SDG)

    9:10 CREATING THE MOST VALUE FROM INTEGRATED THERAPEUTIC AREA STRATEGY AND PORTFOLIO MANAGEMENT

    Dr Mark Seidler

    Dr Mark Seidler, Senior Engagement Manager, Life Sciences Practice, Strategic Decisions Group (SDG)

  • Understanding the difference between TA strategy and portfolio management
  • How to create “joined up thinking” between TA strategy and portfolio management
  • What to do when different processes produce different answers
  • How to gain alignment among different constituencies on the highest value solution
  • 9:40 PATENT PORTFOLIO MANAGEMENT

    Bruce Sunstein

    Bruce Sunstein, Partner, Bromberg & Sunstein

  • Your patent portfolio – what should you protect and why?
  • Best practice strategies
  • Assessing the value of your portfolio
  • Developing an effective innovation culture
  • Choosing the right tools
  • Ensuring a successful outcome
  • 10:20 PROJECT VALUATION WITH OPTION PRICING

    Dr Stephen Black

    Dr Stephen Black, Principal Consultant, PA Consulting

  • Background: what has been promised from options analysis
  • The problem: why people are becoming sceptical about complex options techniques
  • Stepping back to reality: the real problems we are trying to solve: decisions, uncertainty and risk
  • New approaches to options that avoid the mystique and enhance transparency
  • The future of options in project decision making and portfolio risk analysis
  • 11:00 Morning Coffee

    11:20 INTEGRATION OF COMMERCIALISATION IN PORTFOLIO MANAGEMENT

    Alexander Johns

    Alexander Johns, Chairman, bioStrategies Group

  • Seeking to understand how commercialisation affects portfolio management
  • Timing of commercial assessment and forecasting
  • Impact of pharmacoeconomic modelling on portfolio process
  • Factors to consider
  • Overcoming challenges
  • 12:00 PHARMACEUTICAL PORTFOLIO MANAGEMENT IN A FINANCIAL PERSPECTIVE

    Dr Thomas Tscherning

    Dr Thomas Tscherning, Investment Manager, BankInvest Biomedical Venture

  • What does a biotech venture investor look for
  • Big pharma and venture capital – is there a place for co-operation
  • Making the stakeholders win: The Zeuthen Plan
  • Balancing the portfolio
  • 12:40 Networking Lunch

    14:00 PORTFOLIO MANAGEMENT FROM A GOVERNANCE POINT OF VIEW

    Dr Roy Bullingham

    Dr Roy Bullingham, Vice President, Clinical Pharmacology, Pharmacia

  • How portfolio management works now in R & D governance….a user’s perspective
  • Some examples of management failures and their origins
  • Early and late development differences
  • The necessary evil: corporate teams
  • The continued need for including strategy and resource
  • 14:40 ROLLING PORTFOLIO MANAGEMENT

    Nigel Illingworth

    Nigel Illingworth, Managing Consultant, IBM Business Consulting Services

  • Business case
  • Transparent decision processes
  • Agreed roles and responsibilities
  • Appropriate models and analysis
  • Integrated IT systems
  • 15:20 INTEGRATING NEW TECHNOLOGIES INTO THE PORTFOLIO MANAGEMENT PROCESS

    Dr Carl Osborne

    Dr Carl Osborne, Managing Director, SciLucent

  • Overview of portfolio management in the age of “personalised medicine”
  • Technology assessment and due diligence
  • Regulatory issues and impacts
  • Understanding the value of technology on the portfolio (research vs. development)
  • Strategies for maximising the value of new technologies
  • 16:00 Chairman's Closing Remarks followed by Afternoon Tea
    Close of Conference

    +

    Workshops

    Effective Portfolio Management in Pharmaceutical R & D
    Workshop

    Effective Portfolio Management in Pharmaceutical R & D

    The Hatton, at etc. venues
    15th January 2003
    London, United Kingdom

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.